Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
Caroline EvenHung-Ming WangShau-Hsuan LiRoger K-C NganArunee DechaphunkulLi ZhangChia-Jui YenPo Chung ChanSomvilai ChakrabandhuBrigette B Y MaSuebpong TanasanvimonVictor Ho Fun LeePei-Jen LouZujun LiAlexander I SpiraAmmar SukariJoël GuigaySteven McCuneJuan Gonzalez-MaffeSebastian SzpakowskiYao YaoHongzi LiangJennifer MatarazaRomain SéchaudLuigi ManentiDarren Wan-Teck LimPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Spartalizumab demonstrated a safety profile consistent with other anti-PD-1 antibodies. The primary endpoint of median PFS was not met; however, median overall survival and median duration of response were longer with spartalizumab compared with chemotherapy.